Puberty blocker trial will help reduce harm, says Cass report author (opens original article in a new tab)

A trial on puberty blockers for gender-questioning children, led by Kings College London, aims to assess their risks and benefits, with increased safeguards and monitoring. Critics argue it may cause harm and question the ethics of involving minors in such research.

• Dame Hilary Cass states that a puberty blocker trial is essential to reduce harm for gender-questioning children.
• The Pathways trial will assess the impact of puberty blockers on physical, social, and emotional wellbeing, with safeguards and monitoring in place.
• The trial faces legal challenges from campaigners who argue it is unethical and risks irreversible harm to participants.